[Tubulin and its related signal].
Antimitotic agents are expected to exert the high antitumor potency on various solid tumors. One of the determining factors for the sensitivity/resistance to these antimitotic agents is the status of the tubulin to which these drugs bind. Quantitative and qualitative changes such as gene mutations of the beta-tubulin were suspected to be major determining factors. Microtubule-associated proteins and the related signaling by the mitogen-activated protein kinase cascade are also considered to be factors influencing the sensitivity/resistance of the tumor cells to the antimitotic agents. These are promising targets for development of new antimitotic agents.
Nishio
K
K
Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008869:Microtubule-Associated Proteins / Q000502:physiology*; D009369:Neoplasms / Q000737:chemistry; D015398:Signal Transduction; D014404:Tubulin / Q000502:physiology*
D000970:Antineoplastic Agents; D008869:Microtubule-Associated Proteins; D014404:Tubulin; D017871:Calcium-Calmodulin-Dependent Protein Kinases